journal
MENU ▼
Read by QxMD icon Read
search

Neurology® Neuroimmunology & Neuroinflammation

journal
https://www.readbyqxmd.com/read/28331893/striking-basal-ganglia-imaging-abnormalities-in-lgi1-ab-faciobrachial-dystonic-seizures
#1
A Sebastian López Chiriboga, Jason L Siegel, William O Tatum, Jerry J Shih, Eoin P Flanagan
No abstract text is available yet for this article.
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28331892/adem-like-presentation-anti-mog-antibodies-and-ms-pathology-two-case-reports
#2
Peter Körtvélyessy, Markus Breu, Marc Pawlitzki, Imke Metz, Hans-Jochen Heinze, Mike Matzke, Christian Mawrin, Paulus Rommer, Gabor G Kovacs, Christian Mitter, Markus Reindl, Wolfgang Brück, Klaus-Peter Wandinger, Hans Lassmann, Romana Höftberger, Frank Leypoldt
No abstract text is available yet for this article.
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28271078/time-correlation-between-mononucleosis-and-initial-symptoms-of-ms
#3
John Endriz, Peggy P Ho, Lawrence Steinman
OBJECTIVE: To determine the average age of MS onset vs the age at which Epstein-Barr infection has previously occurred and stratify this analysis by sex and the blood level of Epstein-Barr nuclear antigen 1 (EBNA1) antibody. METHODS: Using infectious mononucleosis (IM) as a temporal marker in data from the Swedish epidemiologic investigation of MS, 259 adult IM/MS cases were identified and then augmented to account for "missing" childhood data so that the average age of MS onset could be determined for cases binned by age of IM (as stratified by sex and EBNA1 titer level)...
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28255575/microstructural-visual-system-changes-in-aqp4-antibody-seropositive-nmosd
#4
Frederike C Oertel, Joseph Kuchling, Hanna Zimmermann, Claudia Chien, Felix Schmidt, Benjamin Knier, Judith Bellmann-Strobl, Thomas Korn, Michael Scheel, Alexander Klistorner, Klemens Ruprecht, Friedemann Paul, Alexander U Brandt
OBJECTIVE: To trace microstructural changes in patients with aquaporin-4 antibody (AQP4-ab)-seropositive neuromyelitis optica spectrum disorders (NMOSDs) by investigating the afferent visual system in patients without clinically overt visual symptoms or visual pathway lesions. METHODS: Of 51 screened patients with NMOSD from a longitudinal observational cohort study, we compared 6 AQP4-ab-seropositive NMOSD patients with longitudinally extensive transverse myelitis (LETM) but no history of optic neuritis (ON) or other bout (NMOSD-LETM) to 19 AQP4-ab-seropositive NMOSD patients with previous ON (NMOSD-ON) and 26 healthy controls (HCs)...
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28243613/longitudinally-extensive-myelitis-in-ms-mimicking-neuromyelitis-optica
#5
Daniel Whittam, Maneesh Bhojak, Kumar Das, Anu Jacob
No abstract text is available yet for this article.
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28243612/trigemino-autonomic-headache-and-horner-syndrome-as-a-first-sign-of-granulomatous-hypophysitis
#6
Jeremias Motte, Ilonka Kreitschmann-Andermahr, Anna Lena Fisse, Christian Börnke, Christoph Schroeder, Kalliopi Pitarokoili, Oliver Müller, Carsten Lukas, Johannes van de Nes, Rolf Buslei, Ralf Gold, Ilya Ayzenberg
OBJECTIVE: To report a rare case of incipient granulomatous hypophysitis presenting by atypical trigemino-autonomic cephalalgia (TAC) and Horner syndrome. METHODS: The patient was investigated with repeated brain MRI, CSF examination, thoracic CT, Doppler and duplex ultrasound of the cerebral arteries, and extensive serologic screening for endocrine and autoimmune markers. Written informed consent was obtained from the patient for access to clinical files for research purposes and for publication...
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28210663/maraviroc-in-pml-iris-a-separate-ball-game-under-hiv-infection-and-natalizumab
#7
EDITORIAL
Israel Steiner, Felix Benninger
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28210662/time-course-of-glatiramer-acetate-efficacy-in-patients-with-rrms-in-the-gala-study
#8
Mat D Davis, Natalia Ashtamker, Joshua R Steinerman, Volker Knappertz
OBJECTIVE: To determine the time to efficacy onset of glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40). METHODS: This post hoc analysis of data from the 1-year, double-blind, placebo-controlled phase of the Glatiramer Acetate Low-Frequency Administration study (NCT01067521) of GA40 in patients with relapsing-remitting MS (RRMS) sought to determine the timing of efficacy onset using a novel data-censoring approach. RESULTS: Compared with placebo-treated patients, those receiving GA40 exhibited a >30% reduction in the accumulated annualized relapse rate (ARR) within 2 months of initiating treatment and generally sustained this treatment difference during the 1-year study...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28210661/maraviroc-as-possible-treatment-for-pml-iris-in-natalizumab-treated-patients-with-ms
#9
Sibylle C Hodecker, Klarissa H Stürner, Veit Becker, Birte Elias-Hamp, Brigitte Holst, Manuel A Friese, Christoph Heesen
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28210660/severe-early-natalizumab-associated-pml-in-ms-effective-control-of-pml-iris-with-maraviroc
#10
Gabriel Bsteh, Michael Auer, Sarah Iglseder, Lisa-Maria Walchhofer, Dietmar Langenscheidt, Stefan Koppi, Gabriele Schauer-Maurer, Guenther Stockhammer, Thomas Berger
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28203618/negative-commercial-screening-test-for-paraneoplastic-antibodies-in-a-case-of-opsoclonus
#11
Nicolas Vandenbussche, Catherine Cassiman, Maarten Schrooten, Benjamin Gille, Xavier Bossuyt, Thierry Vincent, Philip Van Damme, Koen Poesen
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28203617/ruxolitinib-treatment-in-a-patient-with-neuromyelitis-optica-a-case-report
#12
Sibylle C Hodecker, Jan-Patrick Stellmann, Sina C Rosenkranz, Kim Young, Brigitte Holst, Manuel A Friese, Christoph Heesen
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28203616/paraneoplastic-cerebellar-degeneration-associated-with-anti-itpr1-antibodies
#13
Giulia Berzero, Yael Hacohen, Lars Komorowski, Madeleine Scharf, Caroline Dehais, Delphine Leclercq, Virginie Fourchotte, Bruno Buecher, Jérôme Honnorat, Francesc Graus, Jean-Yves Delattre, Dimitri Psimaras
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28203615/epstein-barr-negative-ms-a-true-phenomenon
#14
Ruth Dobson, Jens Kuhle, Jaap Middeldorp, Gavin Giovannoni
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28180139/metabolomic-signatures-associated-with-disease-severity-in-multiple-sclerosis
#15
Pablo Villoslada, Cristina Alonso, Ion Agirrezabal, Ekaterina Kotelnikova, Irati Zubizarreta, Irene Pulido-Valdeolivas, Albert Saiz, Manuel Comabella, Xavier Montalban, Luisa Villar, Jose Carlos Alvarez-Cermeño, Oscar Fernández, Roberto Alvarez-Lafuente, Rafael Arroyo, Azucena Castro
OBJECTIVE: To identify differences in the metabolomic profile in the serum of patients with multiple sclerosis (MS) compared to controls and to identify biomarkers of disease severity. METHODS: We studied 2 cohorts of patients with MS: a retrospective longitudinal cohort of 238 patients and 74 controls and a prospective cohort of 61 patients and 41 controls with serial serum samples. Patients were stratified into active or stable disease based on 2 years of prospective assessment accounting for presence of clinical relapses or changes in disability measured with the Expanded Disability Status Scale (EDSS)...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28105460/validity-of-a-pcr-assay-in-csf-for-the-diagnosis-of-neurocysticercosis
#16
Arturo Carpio, Alfredo Campoverde, Matthew L Romo, Lorena García, Luis M Piedra, Mónica Pacurucu, Nelson López, Jenner Aguilar, Sebastian López, Luis C Vintimilla, Ana M Toral, Pablo Peña-Tapia
OBJECTIVE: To prospectively evaluate the validity of a PCR assay in CSF for the diagnosis of neurocysticercosis (NC). METHODS: We conducted a multicenter, prospective case-control study, recruiting participants from 5 hospitals in Cuenca, Ecuador, from January 2015 to February 2016. Cases fulfilled validated diagnostic criteria for NC. For each case, a neurosurgical patient who did not fulfill the diagnostic criteria for NC was selected as a control. CT and MRI, as well as a CSF sample, were collected from both cases and controls...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28105459/mog-antibody-positive-benign-unilateral-cerebral-cortical-encephalitis-with-epilepsy
#17
Ryo Ogawa, Ichiro Nakashima, Toshiyuki Takahashi, Kimihiko Kaneko, Tetsuya Akaishi, Yoshiki Takai, Douglas Kazutoshi Sato, Shuhei Nishiyama, Tatsuro Misu, Hiroshi Kuroda, Masashi Aoki, Kazuo Fujihara
OBJECTIVE: To describe the features of adult patients with benign, unilateral cerebral cortical encephalitis positive for the myelin oligodendrocyte glycoprotein (MOG) antibody. METHODS: In this retrospective, cross-sectional study, after we encountered an index case of MOG antibody-positive unilateral cortical encephalitis with epileptic seizure, we tested for MOG antibody using our in-house, cell-based assay in a cohort of 24 consecutive adult patients with steroid-responsive encephalitis of unknown etiology seen at Tohoku University Hospital (2008-2014)...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28101520/an-observational-study-of-alemtuzumab-following-fingolimod-for-multiple-sclerosis
#18
Mark Willis, Owen Pearson, Zsolt Illes, Tobias Sejbaek, Christian Nielsen, Martin Duddy, Kate Petheram, Caspar van Munster, Joep Killestein, Clas Malmeström, Emma Tallantyre, Neil Robertson
OBJECTIVE: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS: Patients with relapsing MS treated sequentially with fingolimod then alemtuzumab who experienced significant subsequent disease activity were identified by personal communication with 6 different European neuroscience centers. RESULTS: Nine patients were identified...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28101519/delayed-tacrolimus-leukoencephalopathy-a-rare-and-reversible-cause-of-dementia
#19
Diego Barragán-Martínez, Ana Simarro-Díaz, Patricia Calleja-Castaño, Aurelio Hernández-Laín, Ana Ramos-González, Alberto Villarejo-Galende
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28054001/aquaporin-4-antibody-titration-in-nmo-patients-treated-with-rituximab-a-retrospective-study
#20
Paola Valentino, Fabiana Marnetto, Letizia Granieri, Marco Capobianco, Antonio Bertolotto
OBJECTIVE: We undertook an observational retrospective study to investigate the usefulness of aquaporin-4 (AQP4) antibodies (Ab) titration in the management of patients with neuromyelitis optica (NMO) treated with rituximab (RTX) by studying (1) the correlation between AQP4-Ab titer and disease activity, (2) the influence of RTX on antibody levels, and (3) the association between AQP4-Ab levels and responsiveness to RTX. METHODS: A cell-based assay was used for AQP4-Ab titration in 322 serum samples from 7 patients with NMO treated with RTX (median follow-up 65 months), according to a treatment-to-target approach...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
journal
journal
49467
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"